blood diagnostics
-
Thermo Fisher bets big on blood cancer, immune diagnostics with $2.6B Binding Site buyout
Thermo Fisher Scientific’s acquisition of The Binding Site brings a company that specializes in diagnostic tests for blood cancers and immune system disorders. It’s Thermo Fisher’s biggest acquisition since its 2021 buyout of contract research organization PPD.
-
MedCity Influencers, Diagnostics
The role of home-based blood diagnostics in future cancer care
The current pandemic, which has caused treatment delays, is simply another reason that home-based treatment options should become more readily available to cancer patients.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Genalyte is taking the single fingertip blood test to the next level (yet another Theranos competitor)
Here’s a look at a company that could seriously be in the running for Theranos’ biggest competitor.
-
NOWDiagnostics is using quick fingertip-prick blood testing to identify disease, and it’s fully approved… (A step above Theranos?)
NOWDiagnostics CEO Kevin Clark shares about the company’s single fingertip-prick blood testing that could change the way we diagnose diseases as well as detect pregnancy.
Promoted
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
